Type 2 diabetes
Weekly injection

Maximus weight-loss program.

Ozempic®

A once-weekly semaglutide injection that improves insulin sensitivity, reduces appetite, and helps regulate blood sugar, prescribed by your Maximus clinician as part of a personalized weight-loss program.

*Ozempic® is FDA-approved for type 2 diabetes, not for weight loss.
Some clinicians prescribe semaglutide off-label for weight management. Your Maximus clinician will determine whether Ozempic® is appropriate based on your medical history. If you'd prefer FDA-approved semaglutide for weight loss, see Wegovy® Pens →

Personalized doses

View more pricing information →

Starting at $349.99/mo

No hidden fees
No membership

Free discreet shipping
FDA-approved
Board-certified doctors

Split your payment into manageable installments with Klarna.

Get started

Important: thyroid C-cell tumor risk. Semaglutide causes thyroid C-cell tumors in rodents. It is unknown whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Ozempic is contraindicated in clients with a personal or family history of MTC or in clients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Medical consultation required to determine eligibility/if a prescription is clinically appropriate. Results may vary. For full details, important safety information, and restrictions visit: maximustribe.com/safety. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound®, and KwikPen® are registered trademarks, and Foundayo™ is a trademark, of Eli Lilly and Company. Maximus is not affiliated with or endorsed by Novo Nordisk A/S or Eli Lilly and Company.

Get started

Weight Loss Protocol Ozempic starting at $349.99/mo

Get started

Weight change observed across semaglutide clinical studies.

Ozempic® has not been studied specifically as a weight-loss medication. Across studies of adults with type 2 diabetes designed to measure A1C reduction, average body weight changes ranged from 7.1 lb to 14.1 lb, though some participants gained weight.

Important · About these numbers. The weight numbers below are study observations from trials designed to measure A1C reduction in adults with type 2 diabetes. Some participants in those studies gained weight. Individual results vary. For semaglutide outcomes specifically studied for weight loss, see Wegovy® Pens →.

7.1 lb

Avg loss · 0.5 mg dose

Average body weight reduction observed in adults with type 2 diabetes in A1C-focused studies.

SUSTAIN · Novo Nordisk · A1C trial

14.1 lb

Avg loss · 1 mg dose

Average body weight reduction observed in adults with type 2 diabetes in A1C-focused studies on the standard 1 mg maintenance dose.

SUSTAIN · Novo Nordisk · A1C trial

73%

Reached A1C below 7%

Percentage of adults with type 2 diabetes reaching the standard A1C goal on the 0.5 mg dose.

SUSTAIN · Novo Nordisk · A1C trial

ACTIVE INGREDIENT: Semaglutide

DELIVERY: Once-weekly injection

STUDIED POPULATION: Adults with type 2 diabetes

FDA-APPROVED USE: Type 2 diabetes

Get started

A once-weekly GLP-1 receptor agonist.

Semaglutide is a GLP-1 receptor agonist. It stimulates the pancreas to release insulin when blood sugar is elevated, suppresses glucagon, slows gastric emptying, and lowers HbA1c. Appetite reduction and weight effects are secondary observations, not primary mechanism.

Appetite regulation

Semaglutide acts on brain pathways involved in appetite, helping reduce cravings and food intake.

Once-weekly dosing

Same time, same day. Start at 0.25 mg, step up every 4 weeks to a 1 mg or 2 mg maintenance dose.

Slowed gastric emptying

Food stays in your stomach longer, helping you feel fuller for longer between meals.

Side effects

Contact your provider immediately if you have these symptoms. Regular monitoring may be needed to track your response to treatment.

Common side effects may include:

Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain

Headache
Fatigue
Dizziness
Bloating, belching
Hair loss (lower incidence)

Rare, but serious side effects may include:

Acute pancreatitis
Gallbladder disease / cholelithiasis
Acute kidney injury (typically secondary to dehydration from GI side effects)
Hypoglycemia (rare without concomitant insulin or sulfonylurea)
Serious allergic reactions / anaphylaxis
Suicidal thoughts or behaviors (rare; class signal)
Increased heart rate
Vision changes in clients with type 2 diabetes (diabetic retinopathy complications)
Thyroid C-cell tumors (rodent data). Boxed warning class effect: contraindicated in clients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Is Ozempic® right for you?

Best for people who

T2D adults seeking blood sugar control
T2D adults with known heart disease (CV risk reduction)
T2D adults with CKD (CKD progression risk reduction)
Adults seeking semaglutide-based weight management who specifically prefer the Ozempic brand

Off-label weight management · Important disclosure

Your evaluation, ongoing clinician care, and the medication itself are bundled into a single monthly program. Your Maximus clinician determines the right protocol based on your medical history and goals.

For type 2 diabetes management, cardiovascular risk reduction in adults with T2D and known heart disease, or chronic kidney disease progression risk reduction in adults with T2D and CKD — all FDA-approved indications for Ozempic® — discuss with your Maximus clinician.

Medical requirements

Not for clients with type 1 diabetes
No history of medullary thyroid carcinoma or MEN 2 syndrome
Not currently pregnant or breastfeeding
No severe gastrointestinal disease

It's easy to get started.

Complete your evaluation

Answer a few health questions online. Takes about 5 minutes. No appointment needed, no waiting rooms.

Physician review

A board-certified physician reviews your information and determines if semaglutide is right for you.

Treatment delivered

If prescribed, your medication ships directly to your door in discreet, unmarked packaging.

Start my treatment

Weight Loss Treatment FAQs

Is Ozempic® approved for weight loss?

No. Ozempic® is FDA-approved for type 2 diabetes and to reduce the risk of major cardiovascular events in adults with T2D and known heart disease. Some clinicians prescribe semaglutide off-label as part of a weight-loss program. Your Maximus clinician will determine whether Ozempic® is appropriate based on your medical history. If you'd prefer FDA-approved semaglutide specifically for weight loss, see Wegovy® Pens — same active ingredient, on-label for chronic weight management.

Ozempic® vs Wegovy®— what's the difference?

Both contain semaglutide. Ozempic® is FDA-approved for type 2 diabetes, for cardiovascular risk reduction in adults with T2D and known heart disease, and for chronic kidney disease progression risk reduction in adults with T2D and CKD. Wegovy® is FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition, and for cardiovascular risk reduction in adults with overweight or obesity and known heart disease. Same molecule, different indications, different dose ladders. The choice depends on your goals, your medical history, and your insurance coverage.

How much weight will I lose on Ozempic®?

Ozempic® has not been studied specifically as a weight-loss medication. In studies of adults with type 2 diabetes designed to measure A1C reduction, average body weight changes ranged from about 7.1 lb to 14.1 lb, though some participants gained weight. Individual results vary and depend on your protocol, dose, diet, and activity. For semaglutide outcomes specifically from weight-loss trials, see Wegovy® Pens.

How is Ozempic® taken?

Once-weekly subcutaneous self-injection on the same day each week. Start at 0.25 mg for 4 weeks (titration), then step up to 0.5 mg, 1 mg, or 2 mg. Your Maximus clinician will provide instructions and walk you through your first injection.